Fibrillation etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster
Fibrillation etiketine sahip kayıtlar gösteriliyor. Tüm kayıtları göster

19 Mayıs 2014 Pazartesi

Hospitalizations For Atrial Fibrillation Are On The Rise

In latest many years there has been an explosion of curiosity in atrial fibrillation (AF), the most widespread heart rhythm disorder. Though it is sometimes imagined to be reasonably benign, AF increases the threat of stroke if untreated. Even if handled, it can be the source of considerable discomfort and can contribute to extra issues, especially when accompanied by other cardiovascular conditions. Now a new review published in Circulation finds that hospitalizations for AF are on the enhance, and this might have crucial implications for the delivery and economics of wellness care in the coming years.


Researchers analyzed data  from practically 4,000,000 hospitalizations in which AF was the major discharge diagnosis from the many years 2000 by means of 2010. Here are some of their essential findings:


About two-thirds of the patients had been white and above the age of 65.


Above the course of a decade the AF hospitalization price increased by 14.four% (p&lt0.001), from 1552 to 1812 per million men and women per 12 months.


The imply age of individuals was 66 many years for males and 74 for ladies.


A total of 66% of AF patients beneath age 65 were male. In sharp contrast, 61% of AF individuals above age 65 were female.


Overall hospital mortality for AF was one%. Mortality declined from 1.two% at the commence of the study to .9% at the end (p&lt0.001).


There was a huge improve in the amount of sufferers above the age of 80, with the fee rising from 9,361 to 11,045 per million population per year, and these individuals had a drastically greater in-hospital mortality charge. The authors discussed the significance of the developing elderly AF population: ”These figures are alarming as the number of persons aged &gt80 years is expected to boost from eleven.four million in 2008 to 19.five million in 2030 which in flip will lead to an massive enhanced burden on the public overall health technique and related cost of care.”


Median length of keep was 3 days throughout the review, but the value of the hospitalization increased from $ 6,410 to $ eight,439, resulting in an total boost in yearly nationwide value from $ two.15 billion to $ three.46 billion.


The authors reflected on the “economic burden” of AF in the long term:



Long term efforts to minimize this economic burden must be targeted on limiting hospitalizations and length of remain. Specified interventions such as emergency room observation units vs. hospital admission, charge control vs. rhythm handle and use of reduced molecular weight heparin vs. unfractionated heparin have been previously described as potential implies to minimize the price linked with the treatment method of AF.



“Atrial fibrillation is a condition in itself, but it also serves as a marker for the severity of other illnesses,” mentioned Nileshkumar Patel, lead writer of the study, in a press release. Reasons for the rise in AF incorporate elevated longevity and a spike in chance variables such as hypertension, weight problems, rest apnea, and diabetes, he explained.



Hospitalizations For Atrial Fibrillation Are On The Rise

28 Mart 2014 Cuma

New Atrial Fibrillation Guideline Supports New Drugs And Devices

A new guideline for atrial fibrillation (AF) was released on Friday by the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society. Amid other functions, the 2014 Guideline for the Management of Individuals With Atrial Fibrillation incorporates important new details about the new oral anticoagulants and catheter ablation for the therapy of AF signs.


Perhaps the largest change since the earlier 2006 guideline has been the introduction of new oral anticoagulants, which can be utilized in some sufferers as an alternative of warfarin for stroke prevention. The new guideline includes recommendations for the use of dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto, Johnson and Johnson), and apixaban (Eliquis, Pfizer and BristolMyers Squibb). Warfarin continues to be indicated for the therapy of AF in patients who have mechanical heart valves. The new agents are strongly recommended for use in individuals with nonvalvular AF who are unable to preserve a therapeutic INR level with warfarin.


Catheter ablation also will get a powerful recommendation when a rhythm control strategy is wanted in sufferers with symptomatic AF refractory to at least one antiarrhythmic drug. ”As knowledge with RF ablation grows, there has been an enhanced recognition that it can be utilised efficiently as an atrial fibrillation remedy,” explained  Craig T. January, the writing committee’s chair, in a press release.


January also highlighted as substantial the guideline’s recommendation to use a more thorough thromboembolic danger calculator, the CHA2DS2-VASc calculator, to estimate stroke risk. “Most preceding suggestions used a simpler chance calculator,” January explained. “We advocate a much more detailed threat calculator that gives much more data.”


Yet another important distinction from the earlier guideline is the diminished function of aspirin, which was previously utilised for stroke prevention in lower-danger sufferers.”But information showing that aspirin decreases stroke chance is weak,” mentioned January.


The Guideline for the Management of Individuals With Atrial Fibrillation will be published in the Journal of the American School of Cardiology (www.cardiosource.org), Circulation (www.americanheart.org), and Heart Rhythm (www.hrsonline.org).



New Atrial Fibrillation Guideline Supports New Drugs And Devices

25 Şubat 2014 Salı

FDA Approves New Catheter For Treatment Of Atrial Fibrillation

The FDA has granted marketing approval for the Thermocool Smarttouch ablation catheter for use in sufferers with drug-resistant paroxysmal atrial fibrillation (AF), sustained monomorphic ischemic ventricular tachycardia and Type I atrial flutter. The device is manufactured by Biosense Webster, a Johnson &amp Johnson Johnson &amp Johnson firm.


The device, according to the organization, “is the very first therapeutic catheter approved in the U.S. that permits direct and real-time measurement of make contact with force in the course of catheter ablation procedures.”


The new catheter was evaluated in the SMART-AF Trial, which was presented final May possibly at the Heart Rhythm Society meeting (webcast of presentation). At one year there was a 74% all round good results charge in patients treated with the catheter. There were, nonetheless, 4 cases of tamponade among the 160 sufferers who underwent ablation.


“The Thermcool Smarttouch catheter is an important new device that will benefit the electrophysiology neighborhood, as it will enable us to much more precisely handle the amount of make contact with force applied to the heart wall when generating lesions in the course of catheter ablation,” explained Andrea Natale, the Main Investigator of the trial, in a press release. “Data from the Intelligent-AF Trial demonstrated that consistent and stable application of get in touch with force has a important affect on patient outcomes. The use of make contact with force-sensing technological innovation has emerged as a vital instrument in delivering optimal outcomes in the therapy of individuals with atrial fibrillation and represents a significant advancement for the clinical community.”


Other manufacturers of RF ablation devices for AF include Medtronic Medtronic, Boston Scientific Boston Scientific, and St. Jude Medical.



FDA Approves New Catheter For Treatment Of Atrial Fibrillation